Temozolomide resistance in glioblastoma multiforme

Резистентность к темозоломиду при мультиформной глиобластоме
Sang Yong Lee
2016-05-11

DNA repair pathwayGlioblastoma multiformeO6-methylguanine-DNA methyltransferaseTMZ-resistant cell linesTemozolomide resistance
Temozolomide (TMZ) is an oral alkylating agent used to treat glioblastoma multiforme (GBM) and astrocytomas. However, at least 50% of TMZ treated patients do not respond to TMZ. This is due primarily to the over-expression of O 6 -methylguanine methyltransferase (MGMT) and/or lack of a DNA repair pathway in GBM cells. Multiple GBM cell lines are known to contain TMZ resistant cells and several acquired TMZ resistant GBM cell lines have been developed for use in experiments designed to define the mechanism of TMZ resistance and the testing of potential therapeutics. However, the characteristics of intrinsic and adaptive TMZ resistant GBM cells have not been systemically compared. This article reviews the characteristics and mechanisms of TMZ resistance in natural and adapted TMZ resistant GBM cell lines. It also summarizes potential treatment options for TMZ resistant GBMs.
1
At least 50% of patients treated with temozolomide do not respond, indicating substantial therapeutic resistance in glioblastoma and astrocytomas.
2
Both intrinsic resistant cells in established glioblastoma cell lines and experimentally adapted resistant lines are used to study resistance mechanisms and therapies.
3
Potential treatment strategies for temozolomide-resistant glioblastomas are summarized, although the abstract does not specify individual therapies.
4
Temozolomide resistance is primarily associated with MGMT overexpression and/or deficiencies in DNA repair pathways within glioblastoma cells.
5
The review systematically compares characteristics and mechanisms of natural versus acquired temozolomide-resistant glioblastoma cells.

Intrinsic and adaptive temozolomide-resistant glioblastoma multiforme cells and cell lines

The characteristics and mechanisms of temozolomide resistance, along with potential treatment options for resistant glioblastomas

Publication Details
Publication Date
2016-05-11
Journal
Publisher
ISSN
Cited by
1224
Access Type
Author Information
Authors
Sang Yong Lee
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%